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Abstract
Background: Oncogenic human papillomavirus (HPV) infection prevalence is required to determine optimal
vaccination strategies. We systematically reviewed the prevalence of oncogenic cervical HPV infection among
Canadian females prior to immunization.
Methods: We included studies reporting DNA-confirmed oncogenic HPV prevalence estimates among Canadian
females identified through searching electronic databases (e.g., MEDLINE) and public health websites. Two
independent reviewers screened literature results, abstracted data and appraised study quality. Prevalence estimates
were meta-analyzed among routine screening populations, HPV-positive, and by cytology/histology results.
Results: Thirty studies plus 21 companion reports were included after screening 837 citations and 120 full-text
articles. Many of the studies did not address non-response bias (74%) or use a representative sampling strategy
(53%).
Age-specific prevalence was highest among females aged < 20 years and slowly declined with increasing age.
Across all populations, the highest prevalence estimates from the meta-analyses were observed for HPV types 16
(routine screening populations, 8 studies: 8.6% [95% confidence interval 6.5-10.7%]; HPV-infected, 9 studies: 43.5%
[28.7-58.2%]; confirmed cervical cancer, 3 studies: 48.8% [34.0-63.6%]) and 18 (routine screening populations, 8
studies: 3.3% [1.5-5.1%]; HPV-infected, 9 studies: 13.6% [6.1-21.1%], confirmed cervical cancer, 4 studies: 17.1% [6.4-
27.9%].
Conclusion: Our results support vaccinating females < 20 years of age, along with targeted vaccination of some
groups (e.g., under-screened populations). The highest prevalence occurred among HPV types 16 and 18,
contributing a combined cervical cancer prevalence of 65.9%. Further cancer protection is expected from cross-
protection of non-vaccine HPV types. Poor study quality and heterogeneity suggests that high-quality studies are
needed.
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Background
Human Papillomavirus (HPV) is one of the most preva-
lent sexually transmitted infections in the world [1].
Over 100 virus genotypes have been identified and at
least 13 are classified as oncogenic or “high-risk” (HR)
because they are known to cause cervical cancer or
other genital cancers [2,3]. The association between HR
HPV infection and cervical cancer has been well estab-
lished in the literature with HR HPV DNA detected in
nearly 100% of all cervical cancers [4-6].
For nearly half a century, cervical cancer prevention
programs consisted mainly of cervical cancer screening
for early detection of pre-cancerous lesions [7].
Although screening programs are effective, [8] cervical
cancer remains a problem due to a large portion of
women who remain unscreened or under-screened,
[9-14] as well as false negative results on the Papanico-
lau test [15,16]. In 2009, an estimated 1,300 Canadian
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result of this disease [8]. The recent introduction of two
prophylactic vaccines [17,18] offer further reduction of
HPV, yet the most optimal primary and secondary pre-
vention strategies remain unclear [19,20].
Baseline prevalence data is necessary to inform opti-
mal prevention programs and evaluate current and
future prevention strategies [21,22]. Since HPV is not a
reportable disease in Canada, data on HPV prevalence
are widely scattered in the literature and mainly
reported among specific populations. We aimed to con-
solidate the prevalence of DNA-confirmed cervical HPV
infection among Canadian females prior to immuniza-
tion programs through a systematic review and meta-
analysis.
Methods
A systematic review protocol was compiled based on
guidelines from The Cochrane Collaboration [23] and
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses [24]. The protocol is available upon
request.
Eligibility criteria and study selection
Studies reporting DNA-confirmed (i.e., through hybrid
capture I or hybrid capture II (HCI or HCII) or poly-
merase chain reaction (PCR)) HPV prevalence estimates
among Canadian females who were not previously vacci-
nated against HPV were included. Authors of studies
not reporting the sample size were contacted and the
study was excluded if the sample size could not be
obtained. Inclusion was not limited by study design,
publication status, year of dissemination or language of
dissemination.
In order to ensure reliability, a training exercise was
conducted prior to commencing the screening process.
Two independent reviewers screened the search results
for inclusion using a pre-defined relevance criteria form,
obtained the full-text of potentially relevant articles and
screened them to determine inclusion. Discrepancies
were resolved by discussion or the involvement of a
third reviewer.
Information sources and search
Medical Subject Headings and text words related to
the prevalence of HPV cervical infection among Cana-
dian females were used to search MEDLINE (OVID
interface, 1950 to October week 5, 2009), EMBASE
( O V I Di n t e r f a c e ,1 9 8 0t o2 0 0 9w e e k4 4 ) ,T h e
Cochrane Library (Wiley interface), and POPLINE
(Knowledge for health interface 1970 to Nov 2, 2009).
The electronic database search was supplemented by
conducting a targeted search of Canadian public health
websites (e.g., Public Health Agency of Canada, Health
Canada, Institut National de Sante Publique du Que-
bec), websites of organizations that produce guidelines
(e.g., Canadian Agency for Technologies in Health,
Society of Obstetrics and Gynecologists of Canada),
and vaccine manufacturer websites (e.g., GlaxoSmithK-
line, Merck). Furthermore, general Internet searches
were conducted in Google and the first 60 unique hits
were scanned. In addition, the reference lists of
included studies were scanned, the authors’ personal
files were searched, and HPV experts in public health
and industry were emailed to ensure that all potentially
relevant data was obtained.
An experienced information specialist conducted all of
the literature searches. The search strategy for the main
(MEDLINE) search is presented in Additional File 1. It
was peer reviewed by another information scientist
using Peer Review of Electronic Search Strategies
(PRESS) [25]. The main search was modified for the
other databases, as necessary (full search strategies for
the other databases available upon request).
Data collection process and data items
A draft data abstraction form was developed, piloted,
and modified as necessary. Two reviewers abstracted all
of the data using the standardized data abstraction form,
independently. Discrepancies were resolved by discus-
sion or the involvement of a third reviewer.
The data abstracted included study characteristics, (e.
g., study design, period of data collection, sample size,
setting, province or territory and city of study conduct),
participant characteristics (e.g., population, mean age
and standard deviation), HPV detection method (e.g.,
HC-I or HC-II, PCR), PCR primers (e.g., MY09, MY11),
number of HPV positive, as well as the overall HPV pre-
valence. As done in previous reviews of HPV prevalence,
[26-28] we focused on HR HPV types commonly recog-
nized to be associated with cervical cancer. These
included the following HPV types: 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, and 68 [3]. Specimens that were
excluded from study analysis due to inadequate speci-
men integrity (e.g., negative for b-globin) were not
included in the sample size.
Four of the included studies directly compared preva-
lence results for different tests (e.g., PCR versus HC-II)
or methods (e.g., wood versus plastic spatula; cotton
swab versus cytobrush) [29-32]. For these studies, preva-
lence results for the test or method found to be the
most sensitive were abstracted. These included HC-II,
[31,32] plastic spatula, [29] and cytobrush [30]. In some
instances, multiple study publications reported data
from the same population (i.e., companion reports).
When this occurred, the report with the largest sample
size was included and the other report(s) was used for
supplementary data.
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vational studies does not exist [33]. As such, a generic
methodological quality tool was developed and applied
to all of the included studies, regardless of study design
using a similar format that was used in a previous sys-
tematic review [34]. One item was added from The
Cochrane Collaboration’sR i s ko fB i a sT o o lo no u t c o m e
reporting bias, which ensures that all outcomes that
were assessed are reported in the study report [23]. The
f i n a lt o o lc o n s i s t e do ft h es a m pling strategy, sensitivity
of sampling, timing of sampling, non-response bias, out-
come reporting bias, and conflict of interest (Additional
File 2).
Age-specific prevalence synthesis
Studies reporting the age-specific prevalence of HR HPV
infection were plotted and variation due to timing of
data collection, HPV detection methods, and study loca-
tion was noted. In order to ensure consistency across
studies, only studies that collected samples in routine
screening (i.e., routine Papanicolau test) were included
in the plot. These results were described narratively and
not combined via meta-analysis to view the wide hetero-
geneity observed across studies.
Prevalence meta-analyses
HPV prevalence among routine screening populations
was defined as the proportion of individuals who were
positive for HR HPV infection divided by the total
population tested for HPV infection. HPV type-specific
prevalence among routine screening populations was
defined as the proportion of females testing positive for
the specific HR HPV type among all of those testing for
HPV infection. These analyses only included studies of
females engaged in routine screening.
HR HPV prevalence and HR HPV type-specific preva-
lence was also calculated for those testing positive for
HPV infection. These analyses included studies of
females engaged in routine screening, as well as those
returning after a previous abnormal cytological test [35].
HPV type-specific prevalence by cytology or histology
was defined as the proportion of individuals testing
positive for the specific HR HPV type broken down by
the cytological and/or histological category according to
the 2001 Bethesda System (Additional File 3) [36]. Stu-
dies using routine screening, those returning after a pre-
vious abnormal cytological test, as well as those
receiving a biopsy were included in this analysis. Indivi-
duals diagnosed with squamous cell carcinoma of the
cervix and/or aden/adenosquamous carcinoma of the
cervix were included in the confirmed cancer category.
Pooled estimates of type-specific prevalence of HR
HPV infection were derived using a random-effects
model [37]. The 95% CIs were derived based on a
normal distribution. In order to produce conservative
prevalence estimates and corresponding 95% CIs, studies
reporting zero for the number of positives were imputed
as being 0.5. Each HR HPV type was considered indivi-
dually; hence prevalence estimates might include conco-
mitant infection with other HPV types. All analyses
were conducted in SAS 9.1 software (SAS Institute Inc.,
Cary, NC, USA).
Results
Literature search
The literature search resulted in a total of 837 citations
(i.e., titles and abstracts). Thirty study reports
[29-32,35,38-62] plus 21 companion reports [27,28,63-81]
fulfilled the inclusion criteria and were included after
screening 120 full-text articles (Figure 1).
Study characteristics
Data were collected from 1960 [42] to 2007 [48] (Table
1). Sample sizes varied from 46 [38] to 9,620 females
[54]. Most of the included studies reported the actual
number of HPV positive, except for one study, which
reported weighted estimates [39]. Twenty-eight of the
included studies were published in journals and two
were theses [48,55]. Six studies reported infection with
multiple HPV types (i.e., multiple infection), which was
an average of 17.1% (median 4.4%) and ranged from
1.2% to 62.0% [31,39,40,49,58,62].
Figure 1 Study flow.
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53% (16/30) did not use a representative sampling strategy
(i.e., they included individuals with risk factors for HPV
and their results cannot be generalized to the general
population), 17% (5/30) did not use adequate timing of
sampling (e.g., retrospective instead of prospective), and
17% (5/30) did not use sensitive sampling techniques (e.g.
hybridization). Seven studies out of 30 were not relevant
to the non-response bias and response rate methodologi-
cal quality items because they included data from cancer
biopsies (Additional File 4) [38-40,43,45,46,51]. Excluding
these studies, some of the others (35%, 8/23) did not
r e p o r tt h er e s p o n s er a t eo ru s e da ni n a p p r o p r i a t e
approach to calculate the response rate (9%, 2/23). Indivi-
dual methodological quality components for each study
are reported in Table 1.
Age-specific HPV prevalence
The age-specific prevalence was generally highest among
females less than 20 years of age and slowly declined as
age increased, despite widespread heterogeneity across
studies (Figure 2). HPV prevalence among females less
than 20 years of age [31,48,50,58] ranged from 14.1%
among university students [58] to 46.9% among Inuit
females from Nunavut [48]. For women aged 20-25
years, HPV prevalence ranged from 13.0% among uni-
versity students [58] to 24.0% among the general popu-
lation of Ontario [31]. The prevalence among Nunavut
women aged 21-30 years was 31.3% [50] and the preva-
lence of Inuit women from Quebec aged 20-29 years
was 24.5% [48]. Ontario women aged 25-29 years had a
prevalence of 16.4% [31] and Newfoundland women
aged 25-34 years had a prevalence of 11.8% [57].
HPV prevalence among women aged 30-39 years
[31,48,50,54,57] ranged from 7.0% in Newfoundland [54]
to 17.2% among Inuit women from Quebec [48]. For
women aged 40-49 years, [31,48,54] the prevalence ran-
ged from 4.0% in Newfoundland [54] to 8.3% in Ontario
[31]. Prevalence among women aged 50-59 years
[32,48,54] ranged from 2.5% in Newfoundland [54] to
8.9% among women aged 50-54 years in Ontario [32].
For women aged 60-69 years, [48,54] the prevalence
ranged from 1.2% in Newfoundland [54] to 12.5%
among Inuit women from Quebec [48]. Finally, the pre-
valence among Ontario women aged greater than 60
was 11.3% [32]. Overall, age-specific HPV prevalence
estimates were higher for other populations (i.e., those
testing positive for HPV and HPV prevalence by histol-
ogy/cytology) compared to the routinely screened popu-
lations (data not shown).
Meta-analysis results
The meta-analysis results of HPV prevalence among rou-
tine screening populations are presented in Figure 3 and
the three HPV types with the highest prevalence (HPV-
16, -18, and -52) are highlighted here. The studies
included in these analyses were conducted between 1990
and 2007, included an average of 1,019 individuals, and
varied in their study location (British Columbia (BC),
Manitoba (MB), ON, QC) [31,39,48,49,55,58-60,62]. For
HPV-16, the pooled prevalence was 8.6% (95% CI: 6.5-
10.7%); the lowest prevalence estimate was reported
among university students (4.8%); [58] while the highest
prevalence estimate was among participants from a low-
income, inner city population (12.6%) [62]. The pooled
prevalence for HPV-18 was 3.3% (95% CI: 1.5-5.1%)
[31,39,48,49,55,58-60,62]. The lowest prevalence estimate
was 0% among university students, [60] while the highest
prevalence was 11.8% among a low-income, inner city
population [62]. Four studies reported HPV prevalence
for HPV-52 and their pooled prevalence was 2.8% (95%
CI: 1.2-4.4%) [39,48,49,58]. The lowest prevalence esti-
mate was 0% among a sample of university students, [58]
while the highest prevalence estimate was 10.8% among
w o m e np r e s e n t i n gt oa ns e x u a l l yt r a n s m i t t e dd i s e a s e
clinic [49].
The meta-analysis results for HPV prevalence among
HPV-positive are presented in Figure 4 and the three
HPV types with the highest prevalence (HPV-16, -18,
and -31) are highlighted here. The studies included in
these analyses were conducted between 1990 and 2007,
included an average of 985 individuals, and varied in
their study location (e.g., BC, MB, ON, QC)
[31,35,39,48,55,58-60,62]. For HPV-16, the pooled pre-
valence from these nine studies was 43.5% (95% CI:
28.7-58.2%). The lowest prevalence was among Inuit
women (19.4%) [48] and the highest prevalence was
among participants with an abnormal Pap test (76.0%)
[35]. For HPV-18, the pooled prevalence from these
nine studies was 13.6% (95% CI: 6.1-21.1%). The lowest
prevalence was among university students (0%), [60]
while the highest prevalence was from a general popu-
lation sample from a low-income, inner-city area
(36.3%) [62]. For HPV-31, the pooled prevalence was
10.1% (95% CI: 4.8-15.3%), [35,39,49,58-60,62] and ran-
ged from 2.3% among the general population [39] to
24.8% among participants with an abnormal Pap test
[35].
The meta-analysis results according to the Bethesda
classification system are presented in Table 2. The pre-
valence generally increased as the type of cervical lesion
approached cervical cancer. The observed prevalence of
combined HR HPV types for those with negative cytol-
ogy or histology was 40.5% (95% CI: 26.4%-54.6%);
15.7% (95% CI: 9.3%-22.0%) for benign lesions; 40.5%
(95% CI: 26.4%-54.6%) for ASC-US; 73.6% (95% CI:
55.3%-91.8%) for LSIL; and 89.9% (95% CI: 84.8%-95.1%)
for HSIL.
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Reference Study population; year
of data collection;
province(s)
Sample
size
Mean age
(SD) or
age range
Method of
detection
#
cases‡
HPV
types
detected
Overall
HPV
prevalence
(any type)†
HR HPV
prevalence
Methodological
quality
components
Peng
1988 [30]
Patients with abnormal
pap smears
Dates NR
Ontario
200 NR In-situ
hybridization
28
(HR16,
18)
Specific
HPV
types
probed§
NA 14%
(HR16, 18)
1.N, 2.Y, 3.U, 4.N,
5.Y, 6.N, 7.Y
Caussy
1990 [42]
Cases with cervical cancer,
controls with CIN without
cervical cancer
1960-1986
British Columbia
141 35.6 (24) In-situ
hybridization
31 HR-16, 18 22% 17.0% 1.N, 2.Y, 3.U, 4.Y,
5.N, 6.N, 7.Y
Duggan
1990 [29]
Patients referred to
colposcopy clinic
Dates NR
Alberta
119 NR Dot blot
hybridization
28
(HPV
16/18/
33)
HR-16,
18, 33
LR-6, 11
NA 23.5%
(HPV 16/
18/33)
1.N, 2.Y, 3.U, 4.N,
5.Y, 6.N, 7.U
Rohan
1991 [60]
University Students:
Routine Screening
1990
Ontario
105 23 (median
age)
PCR (E7/E6) 19 HR-16,
18, 33
LR-6, 11
12.3% 10.5% 1.Y, 2.Y, 3.Y, 4.N,
5.Y, 6.Y, 7.Y
Guijon
1993 [47]
Patients referred to
colposcopy clinic
1985-1990
Manitoba
409 25.7 (NR) In-situ
hybridization
280 HR-16,
18, 33
LR-6, 11
NA 68.5%
(HPV 16/18)
1.N, 2.Y, 3.Y, 4.N,
5.Y, 6.N, 7.Y
Brisson
1994 [41]
Patients referred to
colposcopy clinic
1988-1989
Quebec
1140 Southern Blot 28.2
(6.6)
HR-16, 18
LR-6, 11
NA 24.3%
(HPV-16)
1.N, 2.Y, 3.Y, 4.N,
5.Y, 6.N, 7.Y
Bosch
1995 [38]
Tumor biopsies of invasive
cervical cancer
1989-1992
Province NR
46 NR PCR (MY09/
MY11)
43 HR-16 93.5% 91.3% 1.NA, 2.Y, 3.NA, 4.
N, 5.N, 6.Y, 7.Y
Duggan
1995 [43]*
[27,68]
Cervical cancer tumour
biopsies
1970-1990
Alberta
76 47.3 (16.7) Dot blot
supplemented
by PCR
53 All 70.0% 65.8% 1.NA, 2.Y, 3.NA 4.
Y, 5.N, 6.Y, 7.Y
Franco
1996 [46]
Cervical cancer tumour
biopsies
1983-1990
Quebec
69 NR PCR (GP5
+/GP6+)
59 HR-16,
18, 31,
33, 35
LR-6, 11
85.5% 40.6%
(HPV 16/18)
1.NA, 2.Y, 3.NA, 4.
N, 5.N, 6.Y, 7.Y
Young
1997 [62]
General Public (Low-
income, inner-city area):
Routine Screening
1992-1995
Manitoba
1263 73% less
than 30
years
PCR (MY09/
MY11)
411 HR-16,
18, 31
LR-6, 11
32.5% 18.0%
(HPV 16/18)
1.N, 2.Y, 3.U, 4.N,
5.Y, 6.Y, 7.Y
Duggan
1997 [44]*
[67,69,70]
Cervical biopsies
NR
Alberta
525 28.0 PCR 249 HR-16,
18, 31,
33, 35
LR-6, 11
47.4% 28.0%
(HPV 16/18)
1.N, 2.Y, 3.U, 4.Y,
5.Y, 6.Y, 7. U
Michael
1999 [55]
University Students:
Routine Screening
NR
Ontario
99 NR PCR (MY09/
MY11)
40 HR-16,
18, 31,
33, 35
LR-6, 11
40.4% 10.1%
(HPV 16/18)
1.N, 2.Y, 3.Y, 4.Y,
5.Y, 6.Y, 7.Y
Hankins
1999 [49]*
[63,64,66,71]
HIV positive
1993-2000
Multiple provinces
375 32.5 PCR (MY09/
MY11)
252 HR-16, 18 67.2% 49.1% 1.N, 2.Y, 3.U, 4.Y,
5.Y, 6.Y, 7.Y
Richardson
2000 [58]
University Students:
Routine Screening
1992-1993
Quebec
375 18-24 PCR (MY09/
MY11)
85 HR- [11]
LR-6,11,53
22.7% 11.8% 1.N, 2.Y, 3.Y, 4.N,
5.Y, 6.Y, 7.U
Sellors
2000a [31]*
[65,74,79]
General Public: Routine
Screening
1998-1999
Ontario
955 (HC-
II);
824
(PCR)
15-49 PCR (MY09/
MY11;
HC-II
110 HR- [11]
LR- [16]
13.3% 12.7%
(HC-II)
1.Y, 2.Y, 3.Y, 4.Y,
5.Y, 6.Y, 7.Y
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Sellors
2000b [35]
Patients recalled after an
Abnormal Pap on Routine
Screening
1996-1997
Ontario
200 31.5 (9.4) HC-II/PCR (L1) 125 HR- [13]
LR-
6,11,42,53
62.5% 90.3% HSIL 1.N, 2.Y, 3.Y, 4.N,
5.Y, 6.Y, 7.Y
Ratnam
2000 [57]
General Public: Routine
Screening
1996-1998
Newfoundland
2098 30 (NR) HC-I/HC-II 227
(HR13)
HR- [13]
LR-
6,11,42,53
NA 10.8% 1.Y, 2.Y, 3.Y, 4.Y,
5.Y, 6.Y, 7.Y
Feoli-
Fonseca
2001 [45]*
[77]
Biopsies suspected of HPV
Dates NR
Quebec
691 26.1 PCR (MY09/
MY11/GP5
+/GP6+)
484 HR- [13] 70.0% 92.0% (CIN
III)
100%
(carcinoma
in situ)
1.NA, 2.Y, 3.NA, 4.
Y, 5.N, 6.Y, 7.Y
Healey
2001 [50]*
[72,73]
General Public (Inuit):
Routine Screening
1999
Nunavut
1290 13-79 HC-II 333 HR- [13] 25.8% 1.Y, 2.Y, 3.Y, 4.Y,
5.Y, 6.Y, 7.Y
Tran-Thanh
2002 [61]*
[80]
Cases with SIL or invasive
cancer and controls with
normal cytology and no
history of cervical disease
1998-2000
Quebec
320 16-73 PCR (MY09/
MY11)
206 HR- [13] 64.4% 1.N, 2.Y, 3.Y, 4.N,
5.Y, 6.Y, 7.Y
Sellors 2002
[32]
General Public: Routine
Screening
1999-2000
Ontario
156 50 and
over
HCII/PCR 13 HR- [13]
LR- [14]
NA 8.3%
(HC-II)
1.N, 2.Y, 3.N, 4.N,
5.Y, 6.Y, 7.U
Richardson
2003 [59]*
[81]
University Students:
Routine Screening
1996-1998
Quebec
621 83% under
age 27
years;
mean age
23 (NR)
PCR (MY09/
MY11)
180 HR- [13] 29% 21.8% 1.N, 2.Y, 3.U, 4.N,
5.Y, 6.Y, 7.Y
Lytwyn
2003 [75]*
[53]
Patients recalled after an
Abnormal Pap: ASCUS or
LSIL only
1995-1998
Ontario
105 30.3 (8.1) HC-II 57
(HR13)
HR- [13]
LR- [14]
NA 54.3% 1.Y, 2.Y, 3.Y, 4.Y,
5.Y, 6.Y, 7.Y
Koushik
2005 [52]*
[76,78]
General Public: Cases with
CIN from colposcopy
clinics, controls with
normal pap from
screening.
2001-2003
Quebec
357
cases,
760
controls
32.0 (9.1)
Cases,
31.7 (10.0)
Controls
PCR (MY09/
MY11)
579 HR- [13] 51.8% 41.8% 1.N, 2.Y, 3.Y, 4.Y,
5.Y, 6.Y, 7.Y
Mayrand
2006 [54]
General Public: Routine
Screening
2002-2004
Quebec, Newfoundland
9620 NR HCII 591 HR- [13]
LR- [24]
NA 6.1% 1.N, 2.Y, 3.Y, 4.Y,
5.Y, 6.Y, 7.Y
Ogilvie
2007 [56]
Sex trade workers or
women with a history of
alcohol or drug abuse
2004-2005
British Columbia
151 39.0 HC-II 43
(HC13)
HR- [13] NA 28.5% 1.N, 2.Y, 3.Y, 4.N,
5.Y, 6.Y, 7.Y
Kapala 2007
[51]
General Public: Routine
Screening
Date NR
Ontario
320 73% age
30 or
greater
HC-II 92
(HR13)
HR- [13] NA 28.8% 1.NA, 2.Y, 3.NA, 4.
N, 5.Y, 6.Y, 7.U
Antionishyn
2008 [40]
Cervical biopsies
1995-1998
Saskatchewan
1355 NR PCR (GP5
+/GP6+)
753 HR- [13] 55.6% 56.8% CIN
III (16 and
18)
1.NA, 2.Y, 3.NA, 4.
N, 5.Y, 6.Y, 7.Y
Hamlin-
Douglas
2008 [48]
General Public (Inuit):
Routine Screening
2002-2007
Quebec
554 35.5 (14.4) PCR (MY09/
MY11)
160 All 28.9% 20.4% 1.Y, 2.Y, 3.N, 4.Y,
5.Y, 6.Y, 7.Y
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as negative for intraepithelial lesion or malignancy was
HPV-16 (7.9%) and the prevalence for each of the
other HR types was less than 5%. Among those classi-
fied with LSIL, the three most prevalent types were
HPV-16 (28.3%), HPV-31 (7.3%), and HPV-18 (5.8%).
Among those classified with HSIL, the three most pre-
valent types were HPV-16 (54.0%), HPV-31 (14.2%),
and HPV-18 (7.9%). Among those with confirmed cer-
vical cancer, the highest prevalence was observed for
HPV-16 (48.8% [95% CI: 34.0-63.6%]) [38,43,61],
followed by HPV-18 (17.1% (95% CI: 6.4-27.9%)
[38,42,43,61], and HPV-45 (7.7%, [95% CI: 2.4-13.0%])
[38,61].
Sensitivity analysis
We conducted a post hoc sensitivity analysis of the
meta-analysis results for key study characteristics includ-
ing study location, study design, HPV detection method,
sample size, and methodological quality. Differences in
prevalence estimates across the included studies were
not identified (data not shown).
Table 1 Study characteristics (Continued)
Moore
2009 [39]
Population-based
estimates weighted by
cytology
2004
British Columbia
4821 13-86 PCR (GP5
+/GP6+)
810 All 16.8% 13.9% 1.NA, 2.Y, 3.NA, 4.
Y, 5.Y, 6.Y, 7.N
Notes: * major publication and other references are companion reports, ‡ number of women positive for human papillomavirus, † calculated by using the
“number of cases” value as the numerator and the “sample size” as the denominator, expressed as a percent. Abbreviations: SD standard deviation, NR not
reported, HC hybrid capture, PCR polymerase chain reaction.
Figure 2 Age-specific HPV prevalence. Abbreviations: Coll collection, NUN Nunavit, HC hybrid capture, n total sample size, ON Ontario, QC
Quebec, PCR polymerase chain reaction, NFLD Newfoundland.
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Page 7 of 15Discussion
To our knowledge, this is the most comprehensive sys-
tematic review for a single country. Other HPV preva-
lence reviews included worldwide data and grouped all
countries in North America together [27,28,65]. The
past reviews included few Canadian studies, while data
from 30 Canadian studies along with 21 companion
reports were included here. Previous reviews focused
on HPV prevalence among cervical cancer [27,28,65],
HIV [82] or healthy individuals [83]. Our review
Figure 3 HPV prevalence meta-analyses among all participants. Note: Each point estimate and 95% confidence interval is a separate meta-
analysis. Abbreviations: HR high risk, HPV human papillomavirus, CI confidence interval.
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Page 8 of 15includes data on the full spectrum of HR HPV infec-
tion, providing a more comprehensive understanding
of the role of HPV genotypes in different manifesta-
tions of infection.
HPV prevalence data are required to provide informa-
tion related to baseline HPV burden of disease when
implementing vaccination programs. All of the included
studies were either conducted prior to HPV vaccination
Figure 4 HPV prevalence meta-analyses among HPV-infected participants. Notes: Each point estimate and 95% confidence interval is a
separate meta-analysis. One study (Aho 2003) included in the HPV prevalence among all participants was not included here because only one
HPV type was examined (HPV-52). Abbreviations: HPV human papillomavirus, CI confidence interval.
Tricco et al. BMC Infectious Diseases 2011, 11:235
http://www.biomedcentral.com/1471-2334/11/235
Page 9 of 15Table 2 Prevalence of HPV by Bethesda classification system
HPV
Type
Bethesda
classification
#
studies
Reference(s) #
cases
Total sample
size
% Prevalence (95% CI) from meta-
analysis
HR‡ Negative† 9 [31,35,39,48,49,51,52,54,57] 1451 15102 40.5% (26.4%-54.6%)
Benign 2 [51] 42 275 15.7% (9.3%-22.0%)
ASC-US 5 [31,39,48,51,53,54] 136 350 40.5% (26.4%-54.6%)
LSIL 10 [31,35,39,45,48,49,51,52,54,57] 928 1563 73.6% (55.3%-91.8%)
HSIL 8 [31,35,39,45,51,54,57,78] 559 628 89.9% (84.8%-95.1%)
Cervical Cancer 2 [51,54] 2 3 *
16 Negative 6 [35,39-41,48,52] 473 6017 7.9% (4.9%-11.0%)
Benign 1 [39] 2 250 *
ASC-US 1 [48] 0 17 *
LSIL 7 [35,39-41,45,48,52] 506 1925 28.3% (15.1%-41.5%)
HSIL 7 [35,39-41,45,48,61] 516 1068 54.0% (45.6%-62.4%)
Cervical Cancer 3 [38,43,61] 81 172 48.8% (34.0%-63.6%)
18 Negative 5 [35,39,40,42,48] 156 4891 3.6% (1.6%-5.6%)
Benign 1 [39] 14 250 *
ASC-US 1 [48] 2 17 *
LSIL 6 [35,39,40,42,48,52] 81 1312 5.8% (3.6%-7.9%)
HSIL 5 [35,39,40,42,48] 47 662 7.9% (3.8%-12.0%)
Cervical Cancer 4 [38,42,43,80] 42 219 17.1% (6.4%-27.9%)
31 Negative 4 [35,39,40,48] 33 4849 2.1% (0.1%-4.1%)
Benign 1 [39] 2 250 *
ASC-US 1 [48] 0 17 *
LSIL 5 [35,39,40,48,52] 76 1241 7.3% (2.7%-11.8%)
HSIL 4 [35,39,40,48] 64 432 14.2% (4.0%-24.5%)
Cervical Cancer 3 [38,43,61] 3 172 1.2% (0.0%-2.73%)
33 Negative 4 [35,39,40,48] 38 4849 0.6% (0.0%-1.3%)
Benign 1 [39] 1 250 *
ASC-US 1 [48] 2 17 *
LSIL 4 [35,39,40,48] 35 884 3.6% (1.2%-6.0%)
HSIL 4 [35,39,40,48] 24 432 5.6% (3.5%-7.8%)
Cervical Cancer 3 [38,43,61] 4 172 2.1% (0.0%-4.2%)
35 Negative 4 [35,39,40,48] 28 4849 0.5% (0.3%-0.8%)
Benign 1 [39] 1 250 *
ASC-US 1 [48] 0 17 *
LSIL 4 [35,39,40,48] 31 884 3.1% (0.3%-6.0%)
HSIL 4 [35,39,40,48] 8 432 1.8% (0.5%-3.0%)
Cervical Cancer 3 [38,43,61] 0 172 *
39 Negative 3 [39,40,48] 11 4770 0.8% (0.0%-2.0%)
Benign 1 [39] 0 250 *
ASC-US 1 [48] 1 17 *
LSIL 3 [39,40,48] 6 860 0.6% (0.0%-1.5%)
HSIL 3 [39,40,48] 2 374 *
Cervical Cancer 2 [38,61] 1 96 *
45 Negative 3 [39,40,48] 31 4770 0.6% (0.4%-0.9%)
Benign 1 [39] 0 250 *
ASC-US 1 [48] 0 17 *
LSIL 3 [39,40,48] 9 860 1.1% (0.4%-1.7%)
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Page 10 of 15or did not include vaccinated individuals. These data
can be used to evaluate current HPV vaccination pro-
gram in the future, including vaccine impact on HR
genotype prevalence. The data are also useful for health
economic evaluations and epidemiological modeling
research. HPV is not a reportable disease so baseline
prevalence data could only be obtained by synthesizing
highly heterogeneous individual studies. A limited num-
ber of studies provide population-based estimates of
HPV prevalence and only one provincial based study
[39] was available for our meta-analyses.
The results can inform optimal vaccination program
scheduling. Our findings indicate that HPV prevalence
was highest among females aged less than 20 years. Some
Table 2 Prevalence of HPV by Bethesda classification system (Continued)
HSIL 3 [39,40,48] 6 374 *
Cervical Cancer 2 [38,61] 8 96 7.7% (2.4%-13.0%)
51 Negative 3 [39] 7 4470 *
Benign 1 [39] 0 250 *
ASC-US 1 [48] 1 17 *
LSIL 3 [39,40,48] 2 860 *
HSIL 3 [39,40,48] 3 374 *
Cervical Cancer 2 [38,61] 0 96 *
52 Negative 4 [39,40,48,52] 41 5530 1.4% (0.1%-2.7%)
Benign 1 [39] 0 250 *
ASC-US 1 [48] 1 17 *
LSIL 4 [39,40,48,52] 50 1217 2.9% (0.8%-5.1%)
HSIL 3 [39,40,48] 9 374 2.4% (0.9%-4.0%)
Cervical Cancer 2 [38,61] 3 96 2.6% (0.0%-7.1%)
56 Negative 3 [39,40,48] 74 4770 1.4% (0.8%-2.0%)
Benign 1 [39] 5 250 *
ASC-US 1 [48] 0 17 *
LSIL 3 [39,40,48] 52 860 5.8% (3.2%-8.3%)
HSIL 3 [39,40,48] 4 374 *
Cervical Cancer 2 [38,61] 2 96 1.6% (0.0%-4.1%)
58 Negative 4 [35,39,40,48] 37 4849 1.0% (0.3%-1.6%)
Benign 1 [39] 0 250 *
ASC-US 1 [48] 0 17 *
LSIL 4 [35,39,40,48] 22 884 2.3% (1.3%-3.3%)
HSIL 4 [35,39,40,48] 11 432 2.0% (0.0%-4.3%)
Cervical Cancer 2 [38,61] 0 96 *
59 Negative 3 [39,40,48] 25 4770 0.5% (0.0%-1.1%)
Benign 1 [39] 2 250 *
ASC-US 1 [48] 1 17 *
LSIL 3 [39,40,48] 9 860 0.9% (0.3%-1.6%)
HSIL 3 [39,40,48] 9 374 2.1% (0.7%-3.6%)
Cervical Cancer 2 [38,61] 0 96 *
68 Negative 3 [39,40,48] 5 4470 *
Benign 1 [39] 0 250 *
ASC-US 1 [48] 0 17 *
LSIL 3 [39,40,48] 1 860 *
HSIL 3 [39,40,48] 2 374 *
Cervical Cancer 2 [38,61] 1 96 *
Notes: *meta-analysis not feasible due to small numbers, †negative for intraepithelial lesion or malignancy, ‡ includes analyses of all HR types combined (i.e.,
multiple-infection). Abbreviations: atypical squamous cells of undetermined significance (ASCUS), low-grade squamous intraepithelial lesions (LSIL), HSIL high-
grade squamous intraepithelial lesions (HSIL).
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Page 11 of 15countries (such as Canada) have publicly funded vaccina-
tion programs targeting pre-adolescent and adolescent
girls and our results support this approach. High age-spe-
cific HR HPV prevalence up to the age of 30 years stresses
the need of evaluating the impact of catch-up vaccination
programs in these older age groups.
Our results indicate that the prevalence of HR HPV
varies among different subgroups of the population with
indications of higher prevalence in those at greater risk
of being under-screened. In our review, socially disadvan-
taged individuals (i.e., living in low-income, inner-city
areas or Aboriginal communities) had the greatest HPV
prevalence. Although declines in incidence and mortality
due to routine screening have occurred, [84] false-nega-
tive Pap test results continue to raise important questions
regarding optimal screening policies [15,16]. Our review
identified a positive HPV test (e.g., 7.9% HPV-16 and
3.6% HPV-18) among females with a negative Pap test.
Both tests have associated sensitivities and specificities,
and while there is continuing research in identifying the
best screening policies with these tests, vaccination
remains an effective method to prevent infection with the
major HR HPV types [85]. In addition to errors due to
diagnostic sensitivity and specificity, 12% of Canadians
never go for a Pap test [9]. Individuals less likely to
obtain the Pap test include those of lower education,
[10,12,13] lower income, [10,12,13] recent immigrants,
[14,86] ethnic minorities, [11] living in rural areas, [11]
and those who are obese [87]. These groups of indivi-
duals merit special attention when implementing and
evaluating HPV vaccination programs.
The HPV vaccines protect against oncogenic strains
HPV-16 and -18. These two HPV types contributed a
combined prevalence of 12% for HR HPV infection and
66% of cervical cancer, which potentially can be pre-
vented by the vaccines assuming 100% efficacy and
long-lasting immunity. These estimates are slightly
lower than previous reviews that reported this estimate
as being approximately 70%, [26] indicating that our
results might be conservative. Emerging data showing
cross-protection against several non-vaccine HR HPV
types is encouraging. According to the bivalent vaccine
product monograph, protection against HPV-31 (accord-
ing to protocol cohort) and -45 (total vaccinated cohort)
was also observed [17]. These two HR HPV types con-
tributed an estimated combined prevalence of 8.9%
(1.2% for HPV-31 and 7.7% for HPV-45) for cervical
cancer, indicating that additional cancer protection is a
possibility. According to the quadrivalent vaccine pro-
duct monograph, there was some cross-protection
against HPV-31, but not against -45 [18]. Ongoing fol-
low-up of clinical trials and national registries can help
understand the potential impact of cross-protection on
HPV-related cancer reduction.
Our results are similar to previous reviews of HPV pre-
valence. The overall HR HPV prevalence observed in our
systematic review was 27.1% among screening popula-
tions, which is lower than the prevalence for any HPV
infection in HIV positive women (36.3%) reported in a
previous review, as expected [82]. In addition, another
previous review found that HPV prevalence peaked in
younger women (≤ 25 years of age) and decreased with
age, which is consistent with our results [83]. Similar to
another review, [65] we found that there was an inconsis-
tent relationship between HPV prevalence in HSIL versus
cervical cancer cases across different HPV types. For
example, we found a higher HPV prevalence in HSIL ver-
sus cervical cancer (including squamous cell carcinoma
of the cervix and/or aden/adenosquamous carcinoma of
the cervix) for HPV 16 (54.0% HSIL versus 48.8% cervical
cancer), 31 (14.2% HSIL versus 1.2% cervical cancer), and
33 (5.6% HSIL versus 2.1% cervical cancer), whereas the
reverse was true for HPV 18 (7.9% HSIL versus 17.1%
cervical cancer) and 52 (2.4% HSIL versus 2.6% cervical
cancer). The relationship between HSIL and cervical can-
cer could not be explored for the other HPV types, due
to insufficient data. Furthermore, many of the cervical
cancer estimates were based on a small number of stu-
dies, making these results difficult to interpret.
We found that multiple infections occurred in 17.1%
of the included prevalence estimates. Multiple infections
occurred in 11.2% of the prevalence estimates in a
review of invasive cervical cancer [26] and 11.9% in a
review limited to women infected with HIV [82]. Factors
that can explain the difference in multiple infections
across reviews include different duration of specific
types of infection (i.e., natural clearance of one or sev-
eral types but persistence of the main one); and/or
potentially different number of new sexual partners dur-
ing the last months in females with LSIL, HSIL and
those with cervical cancer or HIV.
Compared to different regions throughout the world,
HPV prevalence in Canada is moderate. One review found
that the highest prevalence of HPV among middle-aged
women (35-50 years) was observed for Africa, Central and
South America, and the United States (approximately
20%), while a lower prevalence was observed in Asia, Aus-
tralia, Europe, Middle East, and Canada (approximately
15%) [83]. Furthermore, the proportion of cancer cases
associated with HPV 16 and 18 was found to be the high-
est in Africa (94.2%), moderate in North America (89.2%),
and the lowest in Asia (68%) [26].
Limitations of this systematic review include that the
meta-analyses were based on each HPV type individually
so may include concomitant infection. Data were also
pooled across studies using different tests to measure
the presence of HPV (e.g., hybridization, PCR, HC) and
these tests vary in their sensitivity and specificity. For
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Page 12 of 15example, HC-II has been found to be a more sensitive
test versus HC-I [88]. The methodological quality of the
included studies was variable; less than half used a
representative sampling strategy and many had small
sample sizes.
Population-based, high-quality, HPV prevalence stu-
dies are warranted. These studies should report age-spe-
cific prevalence, overlap between single and multiple
infection, and HPV type-specific infection. A recently
published prevalence study from the United Kingdom is
an excellent example of such a study [89]. These data
can lead to a better understanding of HPV prevalence,
as well as the impact of new prevention programs at the
national and international levels.
Conclusions
Prevalence data of cervical human papillomavirus infection
is necessary to inform optimal prevention programs and
evaluate current prevention strategies. Previous HPV pre-
valence reviews included worldwide studies and focused
on HPV prevalence among cervical cancer, HIV or healthy
individuals. To our knowledge, this is the most compre-
hensive systematic review for a single country and the data
can be used in health economic evaluations and epidemio-
logical modeling research to help inform public health pol-
icy. Our results show that the highest prevalence occurred
among females < 20 years of age, yet prevalence remained
high among women up to 30 years of age.
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